THE TALK: Breast Cancer - Episode 2
Interesting Trials in HER2+ Breast Cancer
Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.
Data from the following clinical trials are discussed:
- LBA15 - Primary outcome of the phase 3 SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pretreated HER2-positive locally advanced or metastatic breast cancer
- 139P - HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study